Home Cart Sign in  
Chemical Structure| 163451-81-8 Chemical Structure| 163451-81-8

Structure of Teriflunomide
CAS No.: 163451-81-8

Chemical Structure| 163451-81-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Teriflunomide, the active metabolite of an approved antirheumatic drug leflunomide, is an emerging oral therapy for multiple sclerosis (MS). It reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines.

Synonyms: A77 1726; Flucyamide; SU 20

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Teriflunomide

CAS No. :163451-81-8
Formula : C12H9F3N2O2
M.W : 270.21
SMILES Code : C/C(O)=C(C#N)/C(NC1=CC=C(C(F)(F)F)C=C1)=O
Synonyms :
A77 1726; Flucyamide; SU 20
MDL No. :MFCD00910058
InChI Key :UTNUDOFZCWSZMS-YFHOEESVSA-N
Pubchem ID :54684141

Safety of Teriflunomide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

In Vitro:

Cell Line
Concentration Treated Time Description References
primary rat oligodendroglial precursors 1, 5, 10 μM 24 hours To investigate the effect of Teriflunomide on oligodendroglial cell differentiation, it was found that 5 μM concentration upregulated transcript levels of myelin markers such as CNPase and PLP. PMC5851312
primary rat oligodendroglial precursors 5 μM 24 hours To investigate the effect of Teriflunomide pulse stimulation on oligodendroglial cell differentiation, it was found that a 24-hour pulse increased CNPase protein expression. PMC5851312
U937 cells 10 and 30 μM 24 hours Reduced cytokine secretion (CXCL10, 3-fold; CCL2, 2.5-fold; IL-6, 2.2-fold; p<0.001) PMC5346211
HMC3 cells 10 and 30 μM 24 hours Reduced cytokine secretion (CXCL10, 3-fold; CCL2, 2.5-fold; IL-6, 2.2-fold; p<0.001) PMC5346211
Candida albicans 64 µg/mL 24 hours The combination of teriflunomide and fluconazole showed significant synergistic inhibitory effects on resistant Candida albicans. PMC10758495
murine astrocytes 1, 10, 30 μM 24 hours or 72 hours To investigate the effect of teriflunomide on astrocyte metabolism, it was found that teriflunomide increased glycolytic ATP production at both 24 and 72 hours, with a significant bias toward glycolytic ATP production at 72 hours. PMC8866412
oligodendrocyte precursor cells (OPCs) 10 nM to 5 μM 24, 48, and 96 hours TF decreased OPC proliferation and promoted differentiation at concentrations ranging from 10 nM to 5 μM PMC8515201
acute hippocampal slices 50 µM 30 minutes To investigate the effects of teriflunomide on neuronal activity and mitochondrial function under oxidative stress, results showed that teriflunomide restored tissue respiration and prevented the depression of synaptic transmission. PMC8835718
Candida albicans 64 µg/mL 4 hours The combination of teriflunomide and fluconazole inhibited the immature biofilm formation of resistant Candida albicans. PMC10758495
Choroid plexus epithelial cells 0.1 µM to 2 mM 5 days Teriflunomide significantly reduced JCPyV infection and spread in choroid plexus epithelial cells PMC8468119
Primary human astrocytes 0.1 µM to 2 mM 5 days Teriflunomide significantly reduced JCPyV infection and spread in primary human astrocytes PMC8468119
adult mouse oligodendrocyte precursor cells (OPCs) 10 nM 96 hours TF promoted differentiation of adult OPCs PMC8515201
CD8 T cells 100 µM Teriflunomide inhibited the proliferation of CD8 T cells, and this inhibition could be reversed by the addition of uridine. PMC8552527

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cuprizone-mediated demyelination model Oral 10 mg/kg/day Pulse administration: 7 consecutive days during the fourth week of cuprizone challenge; Continuous administration: final 18 days of cuprizone treatment Teriflunomide efficiently boosted myelin repair activities in the cuprizone-mediated demyelination model, leading to accelerated generation of oligodendrocytes and restoration of myelin sheaths. Moreover, teriflunomide restored mitochondrial integrity within oligodendroglial cells. PMC9826576
Xenopus laevis Mbp:GFP-NTR transgenic Xenopus laevis administered in water 1, 10, and 100 μM for 3 days TF promoted remyelination in Xenopus laevis PMC8515201
Galleria mellonella Galleria mellonella larvae Injection 1.6 µg/larvae Single injection, lasting 4 days The combination of teriflunomide and fluconazole significantly increased the survival rates of Galleria mellonella larvae infected with resistant Candida albicans, and reduced the fungal burden and tissue damage. PMC10758495
Syrian Gold hamsters SARS-CoV-2 infection model Oral 10 mg/kg Twice daily for 6 days Evaluate the inhibitory effect of drug combination on SARS-CoV-2 replication, results showed combination treatment significantly reduced viral load PMC9035612

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02509052 Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << Phase 1 Phase 2 Active, not recruiting June 2019 United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 Less <<
NCT02559765 - Completed - United Kingdom ... More >> The University of Glasgow Glasgow, United Kingdom, G12 8LL Less <<
NCT03709446 Breast Neoplasms ... More >> Breast Diseases Metastatic Triple Negative Breast Cancer Less << Phase 1 Phase 2 Not yet recruiting October 20, 2021 United States, New York ... More >> Icahn School of Medicine at Mount Sinai Not yet recruiting New York, New York, United States, 10029 Contact: Charles Shapiro, MD    212-241-3131    charles.shapiro@mssm.edu    Contact: Joni Gomes, BSN    212-824-7076    joni.gomes@mssm.edu Less <<
NCT02342652 Healthy Elderly Subjects (Age ... More >>≥55 Years) Less << Phase 1 Completed - Singapore ... More >> Singapore, Singapore Less <<
NCT03302442 - Completed - France ... More >> Nantes University Hospital Nantes, France, 44093 Less <<
NCT03535298 Multiple Sclerosis, Relapsing-... More >>Remitting Less << Phase 4 Not yet recruiting September 2023 United States, Ohio ... More >> Cleveland Clinic Not yet recruiting Cleveland, Ohio, United States, 44195 Contact: Tammy Skaramagas, BA    216-445-6724    skaramt1@ccf.org    Principal Investigator: Daniel Ontaneda, MD, MSc          United Kingdom University of Nottingham Not yet recruiting Nottingham, United Kingdom, NG7 2UH Contact: Sara Wilkins    +44 115 9249924 ext 66816    Sara.wilkins@nuh.nhs.uk    Principal Investigator: Nikos Evangelou, MD, DPhil Less <<
NCT03500328 Multiple Sclerosis, Relapsing-... More >>Remitting Less << Not Applicable Recruiting October 31, 2022 -
NCT00273364 Multiple Sclerosis Phase 2 Active, not recruiting December 2018 United States, Illinois ... More >> Northwestern University, Feinberg School of Medicine Chicago, Illinois, United States, 60611 Less <<
NCT02776072 - Completed - -
NCT03399981 - Active, not recruiting December 31, 2023 United States, Massachusetts ... More >> Research Site Cambridge, Massachusetts, United States, 02142 Less <<
NCT02651545 - Recruiting November 30, 2020 United States, New York ... More >> Buffalo General Hospital, D3 Recruiting Buffalo, New York, United States, 14203 Contact: Ralph HB Benedict, PhD    716-859-3484    benedict@buffalo.edu Less <<
NCT03308994 - Recruiting December 31, 2018 France ... More >> Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL) Recruiting Lille, Hauts-de-France, France, 59020 Contact: Arnaud Kwiatkowski, MD-PhD    33320874901    kwiatkowski.arnaud@ghicl.net    University Hospital of Lille Recruiting Lille, Hauts-de-France, France, 59037 Contact: Patrick Vermersch, Professor    33320445765    patrick.vermersch@univ-lille2.fr    University Hospital Center of Caen Recruiting Caen, Normandie, France, 14033 Contact: Gilles-Louis Defer, Professor    33231064617    defer-gi@chu-caen.fr    Contact: Damien Chevanne, PhD    33231064617    chevanne-d@chu-caen.fr    University Hospital of Rouen Recruiting Rouen, Normandie, France, 76031 Contact: Bertrand Bourre, MD    33232888990    Bertrand.Bourre@chu-rouen.fr Less <<
NCT03122652 Multiple Sclerosis Phase 3 Recruiting September 25, 2021 France ... More >> CHU de Bordeaux Recruiting Bordeaux, France, 33000 Contact: Bruno BROCHET, MD          Principal Investigator: Bruno BROCHET, MD          CHRU de Lille Recruiting Lille, France, 59000 Contact: Patrick VERMERSCH, MD          Contact: , MD          Principal Investigator: Patrick VERMERSCH          Hospices Civils de Lyon Recruiting Lyon, France, 69677 Contact: Sandra VUKUSIC, MD          Principal Investigator: Sandra VUKUSIC, MD          Sub-Investigator: Françoise DURAND-DUBIEF, MD          CHRU de Montpellier Recruiting Montpellier, France, 34000 Contact: Pierre LABAUGE, MD          Principal Investigator: Pierre LABAUGE, MD          CHU de Nantes Recruiting Nantes, France Contact: Sandrine WIERTLEWSKI          Principal Investigator: Sandrine WIERTLEWSKI, MD          CHU de Nice Recruiting Nice, France, 06000 Contact: Cassandre LANDES    492034126 ext 33    landes.c@chu-nice.fr    Principal Investigator: Christine LEBRUN-FRENAY, MD, PhD          CHU de Nîmes Recruiting Nîmes, France Contact: Eric THOUVENOT          Principal Investigator: Eric THOUVENOT, MD          APHP - Hôpital La Pitié Salpêtrière Recruiting Paris, France, 75013 Contact: Anne-Caroline PAPEIX, MD          Principal Investigator: Anne-Caroline PAPEIX, MD          Sub-Investigator: Céline LOUAPRE, MD          Sub-Investigator: Elisabeth MAILLART, MD          CHU de Rennes Recruiting Rennes, France, 35000 Contact: Emmanuelle LE PAGE, MD          Principal Investigator: Emmanuelle LE PAGE, MD          CHU de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Jérôme DE SEZE, MD          Principal Investigator: Jérôme DE SEZE, MD          CHU de Toulouse Active, not recruiting Toulouse, France, 31000 Germany University hospital of Charité Not yet recruiting Berlin, Germany Contact: Jens WÜRFEL, MD          Principal Investigator: Jens WÜRFEL, MD          University Hospital of the Ruhr - University Bochum Not yet recruiting Bochum, Germany, D-44791 Contact: Carsten LUKAS, MD          Principal Investigator: Carsten LUKAS, MD          University of Heidelberg Not yet recruiting Heidelberg, Germany, 69120 Contact: Brigitte WILDEMANN, MD          Principal Investigator: Brigitte WILDEMANN, MD          University Medical Center of the Johannes Gutenberg Not yet recruiting Mainz, Germany, 55131 Contact: Frauke ZIPP, MD          Principal Investigator: Frauke ZIPP, MD          Technische Universität München Not yet recruiting Munich, Germany, 81675 Contact: Mark MÜHLAU, MD          Principal Investigator: Mark MÜHLAU, MD          Switzerland University Hospital Basel Not yet recruiting Basel, Switzerland, 4031 Contact: Ludwig Kappos, MD          Principal Investigator: Ludwig Kappos, MD          Turkey Hacettepe University Not yet recruiting Ankara, Turkey Contact: Rana Karabudak, MD          Principal Investigator: Rana Karabudak, MD          Mustafa Kemal University Active, not recruiting Antakya, Turkey Uludag University School of Medicine Active, not recruiting Bursa, Turkey Istanbul University Active, not recruiting Istanbul, Turkey Kocaeli University School of Medicine Active, not recruiting Kocaeli, Turkey Ondokuz Mayis University, Faculty of Medicine Active, not recruiting Samsun, Turkey United Kingdom Queen's Medical Centre Not yet recruiting Nottingham, United Kingdom Contact: Nikos Evangelou, MD          Principal Investigator: Nikos Evangelou, MD Less <<
NCT03277248 Relapsing Multiple Sclerosis (... More >>RMS) Less << Phase 3 Recruiting September 30, 2021 United States, Arizona ... More >> TG Therapeutics RMS Investigational Trial site Recruiting Phoenix, Arizona, United States, 58018 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Colorado TG Therapeutics RMS Investigational Trial Site Recruiting Aurora, Colorado, United States, 80045 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Florida TG Therapeutics RMS Investigational Trial Site Recruiting Tampa, Florida, United States, 33612 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Kentucky TG Therapeutics RMS Investigational Trial Site Recruiting Lexington, Kentucky, United States, 40513 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Missouri TG Therapeutics RMS Investigational Trial Site Recruiting Chesterfield, Missouri, United States, 63017 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Nevada TG Therapeutics RMS Investigational Trial Site Recruiting Las Vegas, Nevada, United States, 89106 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, New Jersey TG Therapeutics RMS Investigational Trial Site Recruiting Teaneck, New Jersey, United States, 07666 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, New Mexico TG Therapeutics RMS Investigational Trial Site Recruiting Albuquerque, New Mexico, United States, 87131 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, New York TG Therapeutics RMS Investigational Trial Site Recruiting Patchogue, New York, United States, 11772 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Ohio TG Therapeutics RMS Investigational Trial site Recruiting Columbus, Ohio, United States, 43221 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Pennsylvania TG Therapeutics RMS Investigational Trial Site Recruiting Pittsburgh, Pennsylvania, United States, 15212 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Texas TG Therapeutics RMS Investigational Trial site Recruiting San Antonio, Texas, United States, 78258 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com    United States, Washington TG Therapeutics RMS Investigational Trial site Recruiting Seattle, Washington, United States, 98122 Contact: TG Therapeutics Clinical Support Team    212-554-4484    RMSclinicalsupport@tgtxinc.com Less <<
NCT03768648 Multiple Sclerosis, Relapsing-... More >>Remitting Less << Not Applicable Not yet recruiting January 2019 France ... More >> CHU de Bordeaux - Service de neurologie Not yet recruiting Bordeaux, France Contact: Bruno BROCHET, Prof    05 56 79 55 21 ext +33    bruno.brochet@chu-bordeaux.fr    Contact: Mathilde DELOIRE, PhD    05 57 82 12 75 ext +33    mathilde.deloire@chu-bordeaux.fr    Principal Investigator: Bruno BROCHET, Prof          Sub-Investigator: Aurélie RUET, MD          Sub-Investigator: Jean-Christophe OUALLET, MD          Sub-Investigator: Cécile DULAU, MD Less <<
NCT02679885 - Recruiting December 2017 United States, Connecticut ... More >> Multiple Sclerosis Treatment Center at Griffin Hospital Recruiting Derby, Connecticut, United States, 06418 Contact: Joseph Guarnaccia, MD    203-732-1290    mstreatmentcenters@griffinhealth.org Less <<
NCT01239459 Renal Impairment Phase 1 Completed - Germany ... More >> Sanofi-Aventis Administrative Office Berlin, Germany Less <<
NCT03277261 Relapsing Multiple Sclerosis (... More >>RMS) Less << Phase 3 Recruiting September 30, 2021 United States, California ... More >> TG Therapeutics RMS Investigational Trial Site Recruiting Carlsbad, California, United States, 92001 TG Therapeutics RMS Investigational Trial Site Recruiting Long Beach, California, United States, 90808 TG Therapeutics RMS Investigational Trial Site Recruiting Pasadena, California, United States, 91105 TG Therapeutics RMS Investigational Trial Site Recruiting Stanford, California, United States, 94305 United States, Florida TG Therapeutics RMS Investigational Trial Site Recruiting Miami, Florida, United States, 33136 United States, Illinois TG Therapeutics RMS Investigational Trial Site Recruiting Northbrook, Illinois, United States, 60062 United States, Kansas TG Therapeutics RMS Investigational Trial Site Recruiting Kansas City, Kansas, United States, 66160 United States, Michigan TG Therapeutics RMS Investigational Trial Site Recruiting Detroit, Michigan, United States, 48201 United States, New York TG Therapeutics RMS Investigational Trial Site Recruiting Amherst, New York, United States, 14226 United States, Ohio TG Therapeutics RMS Investigational Trial Site Recruiting Westerville, Ohio, United States, 43081 United States, Tennessee TG Therapeutics RMS Investigational Trial Site Recruiting Franklin, Tennessee, United States, 37064 TG Therapeutics RMS Investigational Trial Site Recruiting Knoxville, Tennessee, United States, 37922 United States, Texas TG Therapeutics RMS Investigational Trial Site Recruiting Dallas, Texas, United States, 75246 TG Therapeutics RMS Investigational Site Recruiting Round Rock, Texas, United States, 78681 Less <<
NCT00811395 Multiple Sclerosis Phase 2 Completed - United States, New Jersey ... More >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Austria Sanofi-Aventis Administrative Office Wien, Austria Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milano, Italy Spain Sanofi-Aventis Administrative Office Barcelona, Spain United Kingdom Sanofi-Aventis Administrative Office Guildford, United Kingdom Less <<
NCT01863888 Multiple Sclerosis Phase 3 Completed - Belgium ... More >> Investigational Site Number 056001 Brussels, Belgium, 1070 Investigational Site Number 056002 Overpelt, Belgium, 3900 Investigational Site Number 056003 Sijsele-Damme, Belgium, 8340 Germany Investigational Site Number 276-003 Bad Mergentheim, Germany, 97980 Investigational Site Number 276-004 Hannover, Germany, 30625 Investigational Site Number 276-005 Marburg, Germany, 35043 Investigational Site Number 276-007 Mönchengladbach, Germany, 41061 Investigational Site Number 276-001 Münster, Germany, 48149 Investigational Site Number 276-002 Ulm, Germany, 89073 Netherlands Investigational Site Number 528001 Sittard-Geleen, Netherlands, 6162BG Less <<
NCT00811395 - Completed - -
NCT00228163 Multiple Sclerosis Phase 2 Completed - Canada ... More >> Investigational Site Number 16 Calgary, Canada, T2N 2T9 Investigational Site Number 10 Halifax, Canada, B3H 1V7 Investigational Site Number 15 London, Canada, N6A 5A5 Investigational Site Number 12 Montreal, Canada, H2L 4M1 Investigational Site Number 11 Montreal, Canada, H3A 2B4 Investigational Site Number 13 Ottawa, Canada, K1H 8L6 Investigational Site Number 18 Quebec, Canada, G1J 1Z4 Investigational Site Number 14 Toronto, Canada, M5B 1W8 Investigational Site Number 17 Vancouver, Canada, V6T 2B5 Investigational Site Number 19 Winnipeg, Canada, R3E 3N4 France Investigational Site Number 24 Clermont Ferrand Cedex 1, France, 63003 Investigational Site Number 21 Lyon Cedex 03, France, 69394 Investigational Site Number 30 Marseille Cedex 5, France, 13385 Investigational Site Number 23 Montpellier Cedex 5, France, 34000 Investigational Site Number 28 Nice Cedex, France, 06002 Investigational Site Number 27 Rennes Cedex, France, 35033 Less <<
NCT02833714 - Terminated - United States, North Carolina ... More >> University of North Carolina Chapel Hill, North Carolina, United States, 27599 Less <<
NCT02425644 Multiple Sclerosis Phase 3 Active, not recruiting May 15, 2019 -
NCT01881191 - Completed - United States, New York ... More >> Buffalo Neuroimaging Analysis Center Buffalo, New York, United States, 14203 Less <<
NCT03368677 - Recruiting November 2024 Finland ... More >> Turku PET Centre Recruiting Turku, Finland Proper, Finland, 20520 Contact: Laura Airas, MD,professor    023130000    laura.airas@utu.fi Less <<
NCT00883337 Multiple Sclerosis Phase 3 Completed - -
NCT01403376 - Completed - -
NCT01403376 Multiple Sclerosis Phase 2 Completed - Austria ... More >> Investigational Site Number 040001 Wien, Austria, 1010 Canada Investigational Site Number 124005 Calgary, Canada, T2N 2T9 Investigational Site Number 124003 Greenfield Park, Canada, J4V 2J2 Investigational Site Number 124002 London, Canada, N6A 5A5 Investigational Site Number 124007 Montreal, Canada, H3A 2B4 Investigational Site Number 124008 Ottawa, Canada, K1H 8L6 Investigational Site Number 124001 Quebec, Canada, G1J 1Z4 Investigational Site Number 124009 Toronto, Canada, M5B 1W8 Germany Investigational Site Number 276003 Berlin, Germany, 10785 Investigational Site Number 276001 Essen, Germany, 45122 Investigational Site Number 276002 Münster, Germany, 48149 Russian Federation Investigational Site Number 643002 Nizhny Novgorod, Russian Federation, 603076 Ukraine Investigational Site Number 804002 Ivano-Frankovsk, Ukraine, 76008 Investigational Site Number 804001 Kharkiv, Ukraine, 61018 Less <<
NCT00475865 Multiple Sclerosis Phase 2 Completed - United States, New Jersey ... More >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Austria Sanofi-Aventis Administrative Office Vienna, Austria Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milan, Italy United Kingdom Sanofi-Aventis Administrative Office Guildford, United Kingdom Less <<
NCT00751881 Multiple Sclerosis Phase 3 Completed - -
NCT00803049 Multiple Sclerosis Phase 3 Completed - -
NCT00489489 Multiple Sclerosis Phase 2 Completed - United States, New Jersey ... More >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milan, Italy Spain Sanofi-Aventis Administrative Office Barcelona, Spain Less <<
NCT00883337 - Completed - -
NCT00751881 - Completed - -
NCT00134563 Multiple Sclerosis Phase 3 Completed - -
NCT00475865 - Completed - -
NCT00803049 - Completed - -
NCT01252355 - Terminated(Sponsor decision to... More >> prematurely stop the study, not linked to any safety concern.) Less << - -
NCT02587195 Multiple Sclerosis PHASE3 COMPLETED 2021-08-31 CHU de Besan?on, Besan?on, 250... More >>30, France|CHU de Lille, Lille, 59037, France|CHU de Montpellier, Montpellier, 34295, France|CHU de Nice, Nice, 06000, France|CHU de Strasbourg, Strasbourg, 67098, France Less <<
NCT00134563 - Completed - -
NCT00622700 Multiple Sclerosis Phase 3 Completed - -
NCT01252355 Multiple Sclerosis Relapse Phase 3 Terminated(Sponsor decision to... More >> prematurely stop the study, not linked to any safety concern.) Less << - -
NCT00489489 - Completed - -
NCT02792231 Relapsing Multiple Scelrosis Phase 3 Recruiting May 15, 2019 -
NCT02792218 Relapsing Multiple Sclerosis Phase 3 Active, not recruiting May 16, 2019 -
NCT02046629 Multiple Sclerosis Phase 1 Completed - China ... More >> Investigational Site Number 156001 Shanghai, China, 200025 Less <<
NCT02201108 Multiple Sclerosis Phase 3 Active, not recruiting September 2021 -
NCT03198351 - Recruiting February 1, 2022 United States, California ... More >> Investigator Recruiting San Diego, California, United States, 92093 Less <<
NCT00622700 - Completed - -
NCT01895335 Multiple Sclerosis PHASE4 COMPLETED 2025-11-15 Investigational Site Number 84... More >>0077, Birmingham, Alabama, 35209, United States|Investigational Site Number 840007, Cullman, Alabama, United States|Investigational Site Number 840087, Phoenix, Arizona, 85004, United States|Investigational Site Number 840114, Phoenix, Arizona, 85008, United States|Investigational Site Number 840080, Scottsdale, Arizona, 85258, United States|Investigational Site Number 840032, Tucson, Arizona, 85704, United States|Investigational Site Number 840021, Phoenix, Arkansas, United States|Investigational Site Number 840018, Fullerton, California, 92835, United States|Investigational Site Number 840037, Fullerton, California, 92835, United States|Investigational Site Number 840108, Long Beach, California, 90806, United States|Investigational Site Number 840014, Newport Beach, California, 92663, United States|Investigational Site Number 840019, Oceanside, California, 92056, United States|Investigational Site Number 840097, Boulder, Colorado, 80304, United States|Investigational Site Number 840040, Colorado Springs, Colorado, 80907, United States|Investigational Site Number 840046, Denver, Colorado, CO, United States|Investigational Site Number 840016, Englewood, Colorado, 80113, United States|Investigational Site Number 840094, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840024, Bradenton, Florida, FL, United States|Investigational Site Number 840089, Clearwater, Florida, 33756, United States|Investigational Site Number 840055, Coconut Creek, Florida, 33073, United States|Investigational Site Number 840104, Hialeah, Florida, 33013, United States|Investigational Site Number 840101, Miami Lakes, Florida, 33014, United States|Investigational Site Number 840011, Ormond Beach, Florida, United States|Investigational Site Number 840059, Sarasota, Florida, 34239, United States|Investigational Site Number 840008, St. Petersburg, Florida, United States|Investigational Site Number 840081, Sunrise, Florida, 33351, United States|Investigational Site Number 840002, Atlanta, Georgia, 30318, United States|Investigational Site Number 840075, Macon, Georgia, 31210, United States|Investigational Site Number 840012, Fort Wayne, Indiana, United States|Investigational Site Number 840010, Indianapolis, Indiana, United States|Investigational Site Number 840034, Louisville, Kentucky, 40207, United States|Investigational Site Number 840047, Rockport, Maine, 04843, United States|Investigational Site Number 840107, Foxboro, Massachusetts, 02035, United States|Investigational Site Number 840030, Springfield, Massachusetts, 01104, United States|Investigational Site Number 840073, Clinton Township, Michigan, 48035, United States|Investigational Site Number 840068, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840098, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840086, Chesterfield, Missouri, 63017, United States|Investigational Site Number 840058, St. Louis, Missouri, 63110, United States|Investigational Site Number 840026, Lincoln, Nebraska, 68521, United States|Investigational Site Number 840020, Henderson, Nevada, 89012, United States|Investigational Site Number 840049, Freehold, New Jersey, 07728, United States|Investigational Site Number 840044, Toms River, New Jersey, 08755, United States|Investigational Site Number 840100, East Setauket, New York, 11733-345, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840064, NY, New York, 14203, United States|Investigational Site Number 840071, Schenectady, New York, 12308, United States|Investigational Site Number 840091, Staten Island, New York, 10306, United States|Investigational Site Number 840045, Syracuse, New York, 13202, United States|Investigational Site Number 840084, Asheville, North Carolina, 28806, United States|Investigational Site Number 840078, Charlotte, North Carolina, 28204, United States|Investigational Site Number 840042, Raliegh, North Carolina, United States|Investigational Site Number 840105, Sanford, North Carolina, United States|Investigational Site Number 840074, Wilmington, North Carolina, 28401, United States|Investigational Site Number 840090, Winston Salem, North Carolina, 27103, United States|Investigational Site Number 840041, Bismarck, North Dakota, United States|Investigational Site Number 840003, Canton, Ohio, 44718, United States|Investigational Site Number 840009, Dayton, Ohio, United States|Investigational Site Number 840053, Monaca, Pennsylvania, 15061, United States|Investigational Site Number 840056, Philadelphia, Pennsylvania, 19107, United States|Investigational Site Number 840072, Cranston, Rhode Island, 02920, United States|Investigational Site Number 840048, Nashville, Tennessee, 37215, United States|Investigational Site Number 840035, Tullahoma, Tennessee, 37388, United States|Investigational Site Number 840060, Dallas, Texas, 75246, United States|Investigational Site Number 840052, Mansfield, Texas, 76063, United States|Investigational Site Number 840028, San Antonio, Texas, 78229, United States|Investigational Site Number 840070, Henrico, Virginia, 23226, United States|Investigational Site Number 840109, Richmond, Virginia, 23298, United States|Investigational Site Number 840017, Roanoke, Virginia, 24018, United States|Investigational Site Number 840054, Vienna, Virginia, 22182, United States|Investigational Site Number 840069, Spokane, Washington, 99220-3649, United States|Investigational Site Number 840079, Morgantown, West Virginia, 26506-9180, United States|Investigational Site Number 840038, Milwaukee, Wisconsin, 53215, United States|Investigational Site Number 840112, Milwaukee, Wisconsin, United States|Investigational Site Number 840076, Neenah, Wisconsin, 54956, United States|Investigational Site Number 040-001, Linz, Austria|Investigational Site Number 040-002, Wien, Austria|Investigational Site Number 056006, Brasschaat, 2930, Belgium|Investigational Site Number 056001, Bruxelles, 1200, Belgium|Investigational Site Number 056003, Edegem, 2650, Belgium|Investigational Site Number 056002, Kortrijk, 8500, Belgium|Investigational Site Number 056007, Leuven, 3000, Belgium|Investigational Site Number 056008, Liège, 4000, Belgium|Investigational Site Number 056009, Liège, 4000, Belgium|Investigational Site Number 056005, Melsbroek, 1820, Belgium|Investigational Site Number 124006, Cambridge, N1R7L6, Canada|Investigational Site Number 124007, St. John, E2L 4L2, Canada|Investigational Site Number 152003, Concepcion, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 246004, H?meenlinna, 13530, Finland|Investigational Site Number 246005, Kuopio, Finland|Investigational Site Number 246006, Oulu, 90220, Finland|Investigational Site Number 246001, Turku, 20520, Finland|Investigational Site Number 246003, Turku, 20520, Finland|Investigational Site Number 250002, Agen Cedex, 47923, France|Investigational Site Number 250003, Aix En Provence, 13616, France|Investigational Site Number 250004, Albi, 81000, France|Investigational Site Number 250005, Amiens Cedex 1, 80054, France|Investigational Site Number 250006, Bayonne, 64109, France|Investigational Site Number 250007, Bordeaux, 33000, France|Investigational Site Number 250008, Caen, 14000, France|Investigational Site Number 250009, CAHORS Cedex 9, 46005, France|Investigational Site Number 250011, Chambery, 73000, France|Investigational Site Number 250012, Colmar, 68024, France|Investigational Site Number 250001, Dijon, 21000, France|Investigational Site Number 250015, GRENOBLE cedex, 38043, France|Investigational Site Number 250017, Le Mans Cedex 9, 72037, France|Investigational Site Number 250018, Lille Cedex, 59037, France|Investigational Site Number 250019, Limoges Cedex, 87000, France|Investigational Site Number 250020, Lyon Cedex 03, 69275, France|Investigational Site Number 250021, Marseille, 13008, France|Investigational Site Number 250022, Metz-Tessy, 74370, France|Investigational Site Number 250023, Montbeliard, 25200, France|Investigational Site Number 250024, MONTPELLIER Cedex 5, 34295, France|Investigational Site Number 250025, Mulhouse, 68100, France|Investigational Site Number 250026, Nancy, France|Investigational Site Number 250027, Nantes, 44093, France|Investigational Site Number 250028, Nimes, 30029, France|Investigational Site Number 250016, PARIS Cedex 13, 75013, France|Investigational Site Number 250029, PARIS Cedex 20, 75970, France|Investigational Site Number 250043, Pau, 64000, France|Investigational Site Number 250031, Quimper, 29000, France|Investigational Site Number 250032, Reims, 51100, France|Investigational Site Number 250033, Rouen, 76000, France|Investigational Site Number 250030, St Germain En Laye, 78100, France|Investigational Site Number 250035, Strasbourg, 67091, France|Investigational Site Number 250037, Toulouse, 31200, France|Investigational Site Number 250038, Tours, 37044, France|Investigational Site Number 250039, Valence Cedex 9, 26953, France|Investigational Site Number 250040, Valenciennes, 59322, France|Investigational Site Number 250013, VICHY Cedex, 03201, France|Investigational Site Number 276001, Bergisch-Gladbach, 51429, Germany|Investigational Site Number 276003, Berlin, 12099, Germany|Investigational Site Number 276004, Freiburg, 79098, Germany|Investigational Site Number 300002, Athens, 11521, Greece|Investigational Site Number 300001, Athens, 11525, Greece|Investigational Site Number 300005, Larissa, 41110, Greece|Investigational Site Number 300004, Thessaloniki, 546 36, Greece|Investigational Site Number 380008, Ancona, 60126, Italy|Investigational Site Number 380009, Bari, 70124, Italy|Investigational Site Number 380002, Gallarate (VA), 21013, Italy|Investigational Site Number 380001, Milano, 20132, Italy|Investigational Site Number 380004, Milano, 20133, Italy|Investigational Site Number 380006, Napoli, 80138, Italy|Investigational Site Number 380005, Orbassano (TO), 10043, Italy|Investigational Site Number 578002, Bergen, 5021, Norway|Investigational Site Number 578003, Namsos, 7800, Norway|Investigational Site Number 578001, Oslo, 0407, Norway|Investigational Site Number 724002, Barcelona, 08035, Spain|Investigational Site Number 724010, Córdoba, 14004, Spain|Investigational Site Number 724008, Donostia, 20014, Spain|Investigational Site Number 724001, El Palmar (MURCIA), 30120, Spain|Investigational Site Number 724004, La Coru?a, 15006, Spain|Investigational Site Number 724006, Santiago de Compostela, 15706, Spain|Investigational Site Number 724007, Valencia, 46009, Spain|Investigational Site Number 724005, Valladolid, 47011, Spain|Investigational Site Number 752001, Karlstad, 65185, Sweden|Investigational Site Number 752003, Kungsbacka, 43480, Sweden|Investigational Site Number 752002, Motala, 59185, Sweden|Investigational Site Number 826-005, Birmingham, B152TH, United Kingdom|Investigational Site Number 826-003, Brighton, BN25BE, United Kingdom|Investigational Site Number 826-007, Glasgow, G116NT, United Kingdom|Investigational Site Number 826-008, Leeds, LS13EX, United Kingdom|Investigational Site Number 826-010, Leicester, LE54PW, United Kingdom|Investigational Site Number 826-009, London, SW170QT, United Kingdom|Investigational Site Number 826-001, Norwich, nr34dg, United Kingdom|Investigational Site Number 826-006, Romford, RM70AG, United Kingdom|Investigational Site Number 826-004, Salford, M68HD, United Kingdom Less <<
NCT01487096 Multiple Sclerosis Phase 2 Completed - Canada, Ontario ... More >> Canada Toronto, Ontario, Canada France sanofi-aventis France Lyon, France Less <<
NCT01895335 Multiple Sclerosis PHASE4 COMPLETED 2025-11-15 Investigational Site Number 84... More >>0077, Birmingham, Alabama, 35209, United States|Investigational Site Number 840007, Cullman, Alabama, United States|Investigational Site Number 840087, Phoenix, Arizona, 85004, United States|Investigational Site Number 840114, Phoenix, Arizona, 85008, United States|Investigational Site Number 840080, Scottsdale, Arizona, 85258, United States|Investigational Site Number 840032, Tucson, Arizona, 85704, United States|Investigational Site Number 840021, Phoenix, Arkansas, United States|Investigational Site Number 840018, Fullerton, California, 92835, United States|Investigational Site Number 840037, Fullerton, California, 92835, United States|Investigational Site Number 840108, Long Beach, California, 90806, United States|Investigational Site Number 840014, Newport Beach, California, 92663, United States|Investigational Site Number 840019, Oceanside, California, 92056, United States|Investigational Site Number 840097, Boulder, Colorado, 80304, United States|Investigational Site Number 840040, Colorado Springs, Colorado, 80907, United States|Investigational Site Number 840046, Denver, Colorado, CO, United States|Investigational Site Number 840016, Englewood, Colorado, 80113, United States|Investigational Site Number 840094, Fort Collins, Colorado, 80528, United States|Investigational Site Number 840024, Bradenton, Florida, FL, United States|Investigational Site Number 840089, Clearwater, Florida, 33756, United States|Investigational Site Number 840055, Coconut Creek, Florida, 33073, United States|Investigational Site Number 840104, Hialeah, Florida, 33013, United States|Investigational Site Number 840101, Miami Lakes, Florida, 33014, United States|Investigational Site Number 840011, Ormond Beach, Florida, United States|Investigational Site Number 840059, Sarasota, Florida, 34239, United States|Investigational Site Number 840008, St. Petersburg, Florida, United States|Investigational Site Number 840081, Sunrise, Florida, 33351, United States|Investigational Site Number 840002, Atlanta, Georgia, 30318, United States|Investigational Site Number 840075, Macon, Georgia, 31210, United States|Investigational Site Number 840012, Fort Wayne, Indiana, United States|Investigational Site Number 840010, Indianapolis, Indiana, United States|Investigational Site Number 840034, Louisville, Kentucky, 40207, United States|Investigational Site Number 840047, Rockport, Maine, 04843, United States|Investigational Site Number 840107, Foxboro, Massachusetts, 02035, United States|Investigational Site Number 840030, Springfield, Massachusetts, 01104, United States|Investigational Site Number 840073, Clinton Township, Michigan, 48035, United States|Investigational Site Number 840068, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840098, Golden Valley, Minnesota, 55422, United States|Investigational Site Number 840086, Chesterfield, Missouri, 63017, United States|Investigational Site Number 840058, St. Louis, Missouri, 63110, United States|Investigational Site Number 840026, Lincoln, Nebraska, 68521, United States|Investigational Site Number 840020, Henderson, Nevada, 89012, United States|Investigational Site Number 840049, Freehold, New Jersey, 07728, United States|Investigational Site Number 840044, Toms River, New Jersey, 08755, United States|Investigational Site Number 840100, East Setauket, New York, 11733-345, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840064, NY, New York, 14203, United States|Investigational Site Number 840071, Schenectady, New York, 12308, United States|Investigational Site Number 840091, Staten Island, New York, 10306, United States|Investigational Site Number 840045, Syracuse, New York, 13202, United States|Investigational Site Number 840084, Asheville, North Carolina, 28806, United States|Investigational Site Number 840078, Charlotte, North Carolina, 28204, United States|Investigational Site Number 840042, Raliegh, North Carolina, United States|Investigational Site Number 840105, Sanford, North Carolina, United States|Investigational Site Number 840074, Wilmington, North Carolina, 28401, United States|Investigational Site Number 840090, Winston Salem, North Carolina, 27103, United States|Investigational Site Number 840041, Bismarck, North Dakota, United States|Investigational Site Number 840003, Canton, Ohio, 44718, United States|Investigational Site Number 840009, Dayton, Ohio, United States|Investigational Site Number 840053, Monaca, Pennsylvania, 15061, United States|Investigational Site Number 840056, Philadelphia, Pennsylvania, 19107, United States|Investigational Site Number 840072, Cranston, Rhode Island, 02920, United States|Investigational Site Number 840048, Nashville, Tennessee, 37215, United States|Investigational Site Number 840035, Tullahoma, Tennessee, 37388, United States|Investigational Site Number 840060, Dallas, Texas, 75246, United States|Investigational Site Number 840052, Mansfield, Texas, 76063, United States|Investigational Site Number 840028, San Antonio, Texas, 78229, United States|Investigational Site Number 840070, Henrico, Virginia, 23226, United States|Investigational Site Number 840109, Richmond, Virginia, 23298, United States|Investigational Site Number 840017, Roanoke, Virginia, 24018, United States|Investigational Site Number 840054, Vienna, Virginia, 22182, United States|Investigational Site Number 840069, Spokane, Washington, 99220-3649, United States|Investigational Site Number 840079, Morgantown, West Virginia, 26506-9180, United States|Investigational Site Number 840038, Milwaukee, Wisconsin, 53215, United States|Investigational Site Number 840112, Milwaukee, Wisconsin, United States|Investigational Site Number 840076, Neenah, Wisconsin, 54956, United States|Investigational Site Number 040-001, Linz, Austria|Investigational Site Number 040-002, Wien, Austria|Investigational Site Number 056006, Brasschaat, 2930, Belgium|Investigational Site Number 056001, Bruxelles, 1200, Belgium|Investigational Site Number 056003, Edegem, 2650, Belgium|Investigational Site Number 056002, Kortrijk, 8500, Belgium|Investigational Site Number 056007, Leuven, 3000, Belgium|Investigational Site Number 056008, Liège, 4000, Belgium|Investigational Site Number 056009, Liège, 4000, Belgium|Investigational Site Number 056005, Melsbroek, 1820, Belgium|Investigational Site Number 124006, Cambridge, N1R7L6, Canada|Investigational Site Number 124007, St. John, E2L 4L2, Canada|Investigational Site Number 152003, Concepcion, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 246004, H?meenlinna, 13530, Finland|Investigational Site Number 246005, Kuopio, Finland|Investigational Site Number 246006, Oulu, 90220, Finland|Investigational Site Number 246001, Turku, 20520, Finland|Investigational Site Number 246003, Turku, 20520, Finland|Investigational Site Number 250002, Agen Cedex, 47923, France|Investigational Site Number 250003, Aix En Provence, 13616, France|Investigational Site Number 250004, Albi, 81000, France|Investigational Site Number 250005, Amiens Cedex 1, 80054, France|Investigational Site Number 250006, Bayonne, 64109, France|Investigational Site Number 250007, Bordeaux, 33000, France|Investigational Site Number 250008, Caen, 14000, France|Investigational Site Number 250009, CAHORS Cedex 9, 46005, France|Investigational Site Number 250011, Chambery, 73000, France|Investigational Site Number 250012, Colmar, 68024, France|Investigational Site Number 250001, Dijon, 21000, France|Investigational Site Number 250015, GRENOBLE cedex, 38043, France|Investigational Site Number 250017, Le Mans Cedex 9, 72037, France|Investigational Site Number 250018, Lille Cedex, 59037, France|Investigational Site Number 250019, Limoges Cedex, 87000, France|Investigational Site Number 250020, Lyon Cedex 03, 69275, France|Investigational Site Number 250021, Marseille, 13008, France|Investigational Site Number 250022, Metz-Tessy, 74370, France|Investigational Site Number 250023, Montbeliard, 25200, France|Investigational Site Number 250024, MONTPELLIER Cedex 5, 34295, France|Investigational Site Number 250025, Mulhouse, 68100, France|Investigational Site Number 250026, Nancy, France|Investigational Site Number 250027, Nantes, 44093, France|Investigational Site Number 250028, Nimes, 30029, France|Investigational Site Number 250016, PARIS Cedex 13, 75013, France|Investigational Site Number 250029, PARIS Cedex 20, 75970, France|Investigational Site Number 250043, Pau, 64000, France|Investigational Site Number 250031, Quimper, 29000, France|Investigational Site Number 250032, Reims, 51100, France|Investigational Site Number 250033, Rouen, 76000, France|Investigational Site Number 250030, St Germain En Laye, 78100, France|Investigational Site Number 250035, Strasbourg, 67091, France|Investigational Site Number 250037, Toulouse, 31200, France|Investigational Site Number 250038, Tours, 37044, France|Investigational Site Number 250039, Valence Cedex 9, 26953, France|Investigational Site Number 250040, Valenciennes, 59322, France|Investigational Site Number 250013, VICHY Cedex, 03201, France|Investigational Site Number 276001, Bergisch-Gladbach, 51429, Germany|Investigational Site Number 276003, Berlin, 12099, Germany|Investigational Site Number 276004, Freiburg, 79098, Germany|Investigational Site Number 300002, Athens, 11521, Greece|Investigational Site Number 300001, Athens, 11525, Greece|Investigational Site Number 300005, Larissa, 41110, Greece|Investigational Site Number 300004, Thessaloniki, 546 36, Greece|Investigational Site Number 380008, Ancona, 60126, Italy|Investigational Site Number 380009, Bari, 70124, Italy|Investigational Site Number 380002, Gallarate (VA), 21013, Italy|Investigational Site Number 380001, Milano, 20132, Italy|Investigational Site Number 380004, Milano, 20133, Italy|Investigational Site Number 380006, Napoli, 80138, Italy|Investigational Site Number 380005, Orbassano (TO), 10043, Italy|Investigational Site Number 578002, Bergen, 5021, Norway|Investigational Site Number 578003, Namsos, 7800, Norway|Investigational Site Number 578001, Oslo, 0407, Norway|Investigational Site Number 724002, Barcelona, 08035, Spain|Investigational Site Number 724010, Córdoba, 14004, Spain|Investigational Site Number 724008, Donostia, 20014, Spain|Investigational Site Number 724001, El Palmar (MURCIA), 30120, Spain|Investigational Site Number 724004, La Coru?a, 15006, Spain|Investigational Site Number 724006, Santiago de Compostela, 15706, Spain|Investigational Site Number 724007, Valencia, 46009, Spain|Investigational Site Number 724005, Valladolid, 47011, Spain|Investigational Site Number 752001, Karlstad, 65185, Sweden|Investigational Site Number 752003, Kungsbacka, 43480, Sweden|Investigational Site Number 752002, Motala, 59185, Sweden|Investigational Site Number 826-005, Birmingham, B152TH, United Kingdom|Investigational Site Number 826-003, Brighton, BN25BE, United Kingdom|Investigational Site Number 826-007, Glasgow, G116NT, United Kingdom|Investigational Site Number 826-008, Leeds, LS13EX, United Kingdom|Investigational Site Number 826-010, Leicester, LE54PW, United Kingdom|Investigational Site Number 826-009, London, SW170QT, United Kingdom|Investigational Site Number 826-001, Norwich, nr34dg, United Kingdom|Investigational Site Number 826-006, Romford, RM70AG, United Kingdom|Investigational Site Number 826-004, Salford, M68HD, United Kingdom Less <<
NCT03464448 Relapsing Remitting Multiple S... More >>clerosis Less << COMPLETED 2021-10-13 University of Michigan, Ann Ar... More >>bor, Michigan, 48109, United States Less <<
NCT02490982 Relapsing Remitting Multiple S... More >>clerosis Less << COMPLETED 2021-06-28 CHUM, Montréal, Quebec, H2L 4M... More >>1, Canada Less <<
NCT01970410 Multiple Sclerosis Phase 4 Active, not recruiting June 2018 United States, Arizona ... More >> Phoenix Neurological Associates, Ltd Phoenix, Arizona, United States, 85018 United States, New York Multiple Sclerosis Center of Northeastern New York Latham, New York, United States, 12110 United States, Oregon Providence Multiple Sclerosis Center Portland, Oregon, United States, 97225 Less <<
NCT02263547 Teriflunomide Elimination ... More >> Healthy Volunteers Less << Phase 1 Terminated(PK time points were... More >> not being met as expected. Determination that risks outweighed benefit.) Less << - United States, Florida ... More >> USF Carol and Frank Morsani Center for Advanced Healthcare Tampa, Florida, United States, 33612 Less <<
NCT03561402 Multiple Sclerosis, Relapsing-... More >>Remitting Less << COMPLETED 2020-12-30 Department of Pathology, Montr... More >>éal, Quebec, H3A 2B4, Canada Less <<
NCT03526224 - Active, not recruiting November 2019 United States, New York ... More >> Buffalo Neuroimaging Analysis Center Buffalo, New York, United States, 14203 Less <<
NCT04799288 HAM/TSP PHASE1|PHASE2 RECRUITING 2025-08-31 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT06190145 Immune Thrombocytopenia PHASE2 RECRUITING 2025-06-15 Peking University Insititute o... More >>f Hematology, Peking University People's Hospital, Beijing, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.01mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories